Zevra Therapeutics (ZVRA) EBIAT: 2014-2025
Historic EBIAT for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to -$544,000.
- Zevra Therapeutics' EBIAT rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.42%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
- Per Zevra Therapeutics' latest filing, its EBIAT stood at -$544,000 for Q3 2025, which was down 100.73% from $74.7 million recorded in Q2 2025.
- Zevra Therapeutics' 5-year EBIAT high stood at $74.7 million for Q2 2025, and its period low was -$35.7 million during Q4 2024.
- Over the past 3 years, Zevra Therapeutics' median EBIAT value was -$13.2 million (recorded in 2023), while the average stood at -$7.3 million.
- In the last 5 years, Zevra Therapeutics' EBIAT spiked by 622.12% in 2021 and then plummeted by 674.39% in 2024.
- Zevra Therapeutics' EBIAT (Quarterly) stood at -$2.7 million in 2021, then spiked by 312.73% to $5.8 million in 2022, then plummeted by 445.20% to -$19.8 million in 2023, then tumbled by 80.05% to -$35.7 million in 2024, then spiked by 98.36% to -$544,000 in 2025.
- Its EBIAT stands at -$544,000 for Q3 2025, versus $74.7 million for Q2 2025 and -$3.1 million for Q1 2025.